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Background: The composition of gut flora has been proposed as a cause of obesity, a major 
risk factor for type 2 diabetes. The objective of this study was to assess whether serum short 
chain fatty acids, a major by-product of fermentation in gut flora, are associated with obesity 
and/or diabetes-related traits (insulin sensitivity and secretion).
Methods: The association of serum short chain fatty acids levels with measures of obesity 
was assessed using body mass index, computerized tomography scan, and dual photon X-ray 
absorptiometry scan. Insulin sensitivity and insulin secretion were both determined from an 
oral glucose tolerance test and insulin sensitivity was also determined from a hyperinsulinemic 
euglycemic clamp.
Results: In this population of young, obese women, acetate was negatively associated with 
visceral adipose tissue determined by computerized tomography scan and dual photon X-ray 
absorptiometry scan, but not body mass index. The level of the short chain fatty acids acetate, 
but not propionate or butyrate, was also negatively associated with fasting serum insulin and 
2 hour insulin levels in the oral glucose tolerance test.
Conclusions: In this population, serum acetate was negatively associated with visceral   adipose 
tissue and insulin levels. Future studies need to verify these findings and expand on these obser-
vations in larger cohorts of subjects.
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Introduction
Recently, a possible association between the composition of the gut flora and obesity 
has been proposed.1–3 Of importance, it is well described that, in the gut, these   bacteria 
engage in fermentation of certain foods.4 One by-product of fermentation is short 
chain fatty acids (SCFAs). Because SCFAs are predominantly made in the gut, much 
of the research on the action of SCFAs has focused on their role in gastrointestinal 
disease.5 However, SCFAs derived from fermentation are also present in the systemic 
circulation.6 The major SCFA in systemic circulation is acetate (C2), with lower con-
centrations of propionate (C3), and butyrate (C4).6 As SCFAs may be involved in the 
association of gut flora with the development of obesity, we examined the association 
of serum SCFA levels with measures of obesity.7
Obesity is a major risk factor for developing insulin resistance. This insulin resis-
tance leads pancreatic beta cells to secrete more insulin, and if the beta cells cannot 
maintain this higher level of insulin secretion, hyperglycemia occurs and diabetes can 
develop.8 Understanding how obesity leads to impaired insulin sensitivity and why 
pancreatic beta cells may fail to secrete sufficient insulin are important questions. 
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Certain nutrients derived from the diet, such as amino acids 
and free fatty acids,9,10 appear to be involved in both these 
processes. For example, long chain fatty acids (LCFAs) have 
a well-defined role in both insulin secretion and sensitivity,11 
and consequently, have an important role in the development 
of insulin resistance and diabetes. Moreover, LCFAs can be 
a fuel to stimulate insulin secretion, but chronic overexpo-
sure of LCFAs to beta cells leads to impairment in insulin 
secretion; likewise, chronic overexposure to LCFAs leads 
to insulin resistance.11
Importantly, LCFAs are distinct from SCFAs in several 
respects. At the molecular level, LCFAs are larger, more 
water insoluble, and contain over twelve carbons; whereas 
SCFAs are water soluble and contain less than five to six 
  carbons.5 LCFAs are derived primarily from fatty foods, 
whereas SCFAs are derived, at least partially, from fermen-
tation that occurs within the colon.5 To date, limited studies 
have examined whether SCFAs are mediators of either insulin 
action or secretion in humans. One study found a positive 
correlation between propionate and butyrate, but not acetate, 
with steady state plasma glucose, an indirect measure of insu-
lin sensitivity.6 Even less is known about the role of SCFAs in 
insulin secretion. In vitro studies with rodent islets suggested 
an inhibitory effect of SCFAs on glucose-stimulated insulin 
secretion.12 In this study, we examined whether serum SCFA 
levels are associated with insulin action and/or secretion.
Methods
Subjects
The study was approved by the Institutional Review Board 
of Northwestern University. All subjects gave written, 
informed consent. In this cohort of obese (defined as body 
mass index [BMI] over 30) subjects (n = 18), a total of seven 
obese women with polycystic ovary syndrome (PCOS) and 
eleven obese women without PCOS were included. All 
the women were otherwise in good health and not taking 
medications known to affect carbohydrate metabolism for at 
least one month prior to the study, including no antibiotics, 
probiotics, or prebiotics. None of the subjects had fasting 
glucose values diagnostic of diabetes mellitus (Supplemen-
tal Table 1), based on the American Diabetes Association 
criteria.13 Women without PCOS had regular menstrual 
cycles (every 27–35 days) and were without clinical or bio-
chemical evidence of hyperandrogenism. Women with PCOS 
had irregular menstrual cycles (#6 menses per year) and 
elevated total testosterone and/or bioavailable testosterone.14 
Other diagnoses were excluded in the women with PCOS as 
described previously.15 Height, weight, and blood pressure 
were obtained, and BMI was determined in all subjects. 
Serum acetate, propionate, and butyrate were measured in 
a fasting serum sample by gas chromatography as before.16 
Briefly, an 800 µL serum aliquot was filtered and the protein-
free filtrate was stored at 20°C before vacuum distillation. 
The distillation was performed using a 225 µL protein-free 
sample with a 25 µL internal standard solution added.16 Next, 
gas chromatography was performed16 and SCFA concentra-
tions determined as before.16
Body composition and fat distribution
All participants who fulfilled the study entry criteria had their 
body composition determined by dual photon X-ray absorp-
tiometry (DEXA) (Hologic, Bedford, MA) as described 
before17 and visceral adipose tissue (VAT) determined by 
computerized tomography (CT) scan (Siemens, Munich, 
Germany), with slice analysis from the L2–3 vertebral 
interspace.18
Metabolic testing
For 3 days prior to the study, all subjects were advised to 
consume a 300 g/day carbohydrate weight-maintaining diet. 
All subjects underwent a 75 gm oral glucose tolerance test 
(OGTT) in the morning after an overnight fast (10–12 hours). 
Glucose and insulin levels were obtained every 30 minutes 
for 3 hours.
Sequential three-dose hyperinsulinemic   euglycemic 
clamps were performed as previously described.15 
Briefly, a retrograde placed catheter in a hand vein heated 
to above 40°C was used for collection of arterialized blood 
samples. A second catheter was placed in the antecubital vein. 
A primed, continuous infusion of [6,62H]-glucose (Isotec, 
Miamisburg, OH) was infused at a dose of 0.065 mg/min/kg 
for 3 hours before initiation of the insulin infusion. After 
baseline glucose and insulin levels were obtained, a primed 
continuous infusion of insulin was started at a dose of 
10 mU/m2/min. Somatostatin was concurrently infused at a 
dose of 30 ng/kg/min, suppressing endogenous insulin secre-
tion so that plasma insulin levels could be matched across 
the study groups. After 150 minutes, the insulin infusion 
was increased to 20 mU/m2/min for 150 minutes and then 
increased to a dose of 400 mU/m2/min for 90 minutes, as 
this is the dose at which maximal rates of insulin-mediated 
glucose disposal are achieved.17 The glucose levels were 
clamped with a variable infusion of 20% glucose enriched 
to 1.6% atom percent excess with [6,62H]-glucose. Arte-
rialized blood samples were obtained every 5 minutes for 
glucose, every 15 minutes for insulin, and every 10 minutes 
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at   baseline and during the last 40 minutes of each insulin 
infusion dose for [6,62H]-glucose. Endogenous glucose 
production (EGP) and insulin mediated glucose disposal 
(IMGD) were calculated as before,15 and the maximal 
IMGD was used for analyses. The disposition index was 
calculated as the product of the clamp insulin sensitivity 
(defined as glucose disposal corrected for change in plasma 
insulin from baseline) by insulin response during the OGTT 
(0–30 minute, ∆I30). Of note, disposition index values were 
only able to be calculated for 13 of the 18 subjects.
Statistical analysis
Values are reported as the mean + SD unless otherwise 
indicated. P-values were calculated by Student’s t-test (two-
tailed) with a significance level at P , 0.05 using GraphPad 
Prism 5 (GraphPad Software, Inc, San Diego, CA). Pearson 
product-moment correlation coefficients were determined 
with GraphPad Prism 5.
Results
Population characteristics
A group of 18 obese Caucasian women were studied. Seven of 
these subjects had a diagnosis of PCOS. Besides the expected 
differences in serum testosterone, unbound testosterone, and 
DHEA-S between women with and without PCOS, there were 
no differences in age, height, weight, BMI, waist circumfer-
ence, and blood pressure (Table 1). Serum SCFA levels also 
did not differ between the two groups (Table 1).
No difference in measures of obesity was observed 
in this cohort based on PCOS diagnosis (Supplemental 
Table 1). The only differences between the PCOS and 
non-PCOS subjects in measures from the OGTT were the 
2-hour insulin and glucose levels (Supplemental Table 1). 
Specifically, the 2-hour glucose and 2-hour insulin levels 
in the PCOS subjects were higher (P , 0.05) than the 
non-PCOS subjects, which is an expected difference (see 
discussion). No other difference in measures derived from 
the OGTT and hyperinsulinemic euglycemic clamp stud-
ies were observed in this cohort based on PCOS diagnosis 
(Supplemental Table 1).
Association of SCFAs with obesity  
and insulin sensitivity/secretion
When the participants were considered as a single cohort, 
BMI was not correlated with fasting serum SCFA levels 
(Table 2), but serum acetate was negatively correlated 
(P , 0.05) with VAT as determined by CT scan (Table 2 and 
Figure 1A). Propionate and butyrate were not correlated with 
VAT. Serum acetate levels were also negatively correlated 
with fasting and 2-hour insulin levels in the OGTT (Table 2 
and Figure 1B). Propionate and butyrate levels were not cor-
related with any measures determined from the OGTT. In this 
population, there were no significant correlations of SCFA 
Table 1 Descriptive characteristics and short chain fatty acid 
levels in a cohort of 18 obese women
Variables Total  
(n = 18)
PCOS  
(n = 7)
Non-PCOS  
(n = 11)
Pa
Age (years) 29 (5) 29 (4) 28 (6) 0.83
height (cm) 162 (8) 160 (8) 163 (9) 0.54
Weight (kg) 96 (17) 90 (22) 100 (12) 0.26
Systolic BP (mm hg) 115 (9) 113 (10) 116 (8) 0.50
Diastolic BP (mm hg) 69 (7) 69 (8) 70 (6) 0.89
BMI (kg/m2) 37 (7) 35 (6) 38 (8) 0.36
Waist (cm) 105 (12) 103 (14) 106 (11) 0.56
Testosterone (ng/dL) 40 (30) 66 (34) 24 (7) 0.0009
uTestosterone (ng/dL) 16 (12) 27 (12) 9 (3) 0.0002
DhEA-S (ng/mL) 1715 (840) 2364 (818) 1303 (564) 0.005
ShBg (nmol/L) 36 (18) 38 (20) 34 (18) 0.72
Acetate (µM) 24.8 (12.1) 21.1 (14.9) 27.2 (9.9) 0.31
Propionate (µM) 1.4 (0.3) 1.3 (0.2) 1.4 (0.3) 0.55
Butyrate (µM) 0.5 (0.2) 0.5 (0.2) 0.5 (0.2) 0.74
Notes: Values are the mean and standard deviation (in parentheses). aP-values are shown 
in this column comparing parameters between PCOS versus non-PCOS subjects.
Abbreviations:  PCOS,  polycystic  ovary  syndrome;  BP,  blood  pressure; 
BMI,  body  mass  index;  uTestosterone,  bioavailable  testosterone;  DhEA-S, 
dehydroepiandrosterone sulfate; ShBg, sex hormone-binding globulin.
Table  2  Associations  between  short  chain  fatty  acids  and 
measures of obesity and insulin action/secretion
Measures Acetate  
(μM)
Propionate  
(μM)
Butyrate   
(μM)
Obesity
BMI (kg/m2) -0.16 -0.02 0.16
VAT -0.52 (0.03)a 0.16 0.15
FAT (kg) -0.38 0.31 0.11
OGTT
Fasting glucose (mg/dL) -0.21 0.04 0.22
2-hour glucose (mg/dL) -0.43 -0.08 0.01
Fasting insulin (µU/mL) -0.56 (0.02)a 0.25 0.21
2-hour insulin (µU/mL) -0.63 (0.01)a 0.24 0.32
Clamp
EgP (mg/m2/min) 0.31 0.43 0.34
DI (IS × ∆I30) -0.20 0.09 -0.06
MCr (mL/min) -0.09 0.19 -0.25
IMgD (mg/m2/min) 0.33 -0.13 0.28
Notes: aP-values reaching statistical significance are indicated in the parentheses. 
VAT was determined by computerized tomography scan, and FAT was determined 
by dual photon X-ray absorptiometry scan. Values are the correlation coefficients 
(Pearson) between short chain fatty acids and measures of obesity and values derived 
from the oral glucose tolerance test and hyperinsulinemic euglycemic clamp.
Abbreviations:  BMI,  body  mass  index;  VAT,  visceral  adipose  tissue; 
FAT,  percentage  fat  mass  ×  body  weight;  OgTT,  oral  glucose  tolerance  test; 
EgP,  endogenous  glucose  production;  DI,  disposition  index;  MCr,  metabolic 
clearance rate of insulin; IMgD, insulin mediated glucose disposal.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
51
Association of adiposity with acetateDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5
Our results demonstrate the novel observation that serum 
acetate levels are negatively associated with VAT. 
Interestingly, BMI was not associated with serum acetate 
levels. While it is not clear why BMI, which is closely related 
to VAT, was not correlated with serum acetate levels, it is 
important to note that VAT is, in general, considered a more 
accurate measure of adiposity than BMI.20 Additionally, VAT 
is thought to be the metabolically active fat as it is strongly 
associated with metabolic disease.21 This likely relates, in 
part, to the drainage of blood from VAT into the portal 
system where it can affect liver nutrient metabolism; this 
is different than the drainage of blood from subcutaneous 
adipose tissue.22 Given the important role of VAT, the novel 
association observed here needs to be further explored.
In this study, only the level of acetate, and not levels of 
the other SCFAs, was correlated with VAT. Importantly, 
acetate is the major SCFA generated during gut fermenta-
tion and is also the only SCFA to reach high levels in the 
general systemic circulation.5 The other SCFAs, propionate 
and butyrate, are thought to be more quickly metabolized in 
the body upon absorption.5 However, it should be mentioned 
that other sources of SCFAs besides the gut exist, so it can-
not be concluded that gut-derived acetate alone is associated 
with VAT. Furthermore, regarding acetate metabolism, other 
processes, including aging,23 alcohol use,24 and comorbid 
illnesses25,26 can lead to altered acetate levels.
While the data in the present study suggest an asso-
ciation of a SCFA with adiposity, an important question is 
the mechanism underlying this association. One potential 
mechanism is via binding of SCFAs to GPR41 and GPR43, 
the known receptors for SCFAs. These receptors have been 
shown to have a role in regulating leptin and glucagon-like 
pepetide-1 secretion, two hormones involved in regulating 
adiposity.27,28 Interestingly, GPR41 and GPR43 are expressed 
broadly including in immune cells,29 adipose tissue,30 distal 
ileum/colon,31,32 skeletal muscle,33 and pancreatic islets.34 
With this broad tissue distribution of these receptors, deter-
mining precisely how these receptors may be related to 
adiposity will require more extensive investigation.
We also examined the relationship between serum SCFAs 
and insulin action/secretion as determined from an OGTT 
and hyperinsulinemic euglycemic clamp. We found that 
serum acetate was negatively correlated with fasting   insulin 
and 2-hour insulin in the OGTT. This relationship may 
be explained by the association between VAT and fasting 
insulin,35 as these two parameters had a strong positive asso-
ciation in this study (Pearson correlation coefficient = 0.66, 
P , 0.003). Moreover, the association of VAT and fasting 
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Figure 1 Scatter plots showing the association between acetate and visceral adipose 
tissue (A) and fasting insulin (B).
levels with measures determined from the hyperinsulinemic 
euglycemic clamp studies (Table 2).
Next, we examined the groups separately based on PCOS 
diagnosis. As seen in Supplemental Table 2, similar correla-
tions of acetate with VAT were observed for non-PCOS and 
PCOS subjects, compared to that observed when the groups 
were analyzed together (Table 2), but these correlations did 
not reach statistical significance (Supplemental Table 2). 
Likewise, when participants were stratified based on PCOS 
diagnosis, similar correlations between acetate with fasting 
and 2-hour insulin levels from the OGTT data were observed 
(Supplemental Table 2) to those observed considering the 
cohort together (Table 2). However, the association between 
acetate and fasting insulin was the only correlation that 
reached statistical significance in the non-PCOS cohort 
(Supplemental Table 2).
Discussion
Fatty acids have well described roles in both obesity and 
insulin sensitivity and secretion.19 However, most studies 
have focused on LCFAs containing more than twelve carbons. 
Little is known about the role of SCFAs (less than six carbon 
atoms) in these processes. Because of this, we examined 
the relationship between SCFAs and measures of adiposity. 
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
52
Layden et alDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5
insulin with acetate levels was interdependent, as the relation-
ship of VAT to acetate was not significant when controlling 
for fasting insulin (and vice versa), as determined in multiple 
regression analysis (data not shown).
An important limitation of this study is that this cohort 
included both non-PCOS and PCOS subjects. As expected, 
these two groups of subjects exhibited differences in andro-
gen levels as well as measures from the OGTT. However, no 
differences between the groups were observed in the mea-
sures from the clamp studies, even though there is known to 
be other differences in matched populations of PCOS versus 
non-PCOS subjects, specifically IMGD.15 A difference in 
IMGD was not observed here, likely because the PCOS and 
non-PCOS cohorts were not matched and also the sample 
size was small. However, trends in IMGD were seen in the 
expected direction (Supplemental Table 1). Importantly, the 
major correlations between acetate with VAT and insulin lev-
els that were observed when considering the cohort together 
were similar to correlations when the cohort was stratified by 
PCOS diagnosis, suggesting that the observed associations 
may be independent of the diagnosis of PCOS.
Other limitations of this study include the small sample size 
and a relatively homogenous population, as all the subjects were 
obese women. Moreover, variables that alter acetate levels such 
as age, alcohol intake, and other illnesses were not controlled for 
in this study. However, the novel findings here of an associa-
tion of acetate levels with metabolically active visceral fat and 
insulin levels merits further study in larger and more diverse 
cohorts. For example, it will be important to determine if the 
association of serum acetate with VAT is present in non-obese 
and/or type 2 diabetic populations. In summary, these data pro-
vide the first evidence of an association between serum acetate 
levels and measures of obesity and insulin levels.
Acknowledgments
BT Layden is supported in part by Grant Number K12 
HD055884 from the Eunice Kennedy Shriver National 
Institute of Child Health and Human Development and also 
by an Endocrine Fellows Foundation Grant.
Disclosure
The authors declare no conflicts of interest in this work.
References
1.  Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity 
is linked to marked but reversible alterations in the mouse distal gut 
microbiome. Cell Host Microbe. 2008;3(4):213–223.
2.  Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and 
obesity. J Physiol. 2009;587(Pt 17):4153–4158.
  3.  Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER,   
Gordon JI. An obesity-associated gut microbiome with increased   
capacity for energy harvest. Nature. 2006;444(7122):1027–1031.
  4.  Samuel BS, Shaito A, Motoike T, et al. Effects of the gut micro-
biota on host adiposity are modulated by the short-chain fatty-acid   
binding G protein-coupled receptor, Gpr41. Proc Nat Acad Sci U S A. 
2008;105(43):16767–16772.
  5.  Wong JM, de Souza R, Kendall CW, Emam A, Jenkins DJ. Colonic 
health: fermentation and short chain fatty acids. J Clin Gastroenterol. 
2006;40(3):235–243.
  6.  Wolever TM, Josse RG, Leiter LA, Chiasson JL. Time of day and glu-
cose tolerance status affect serum short-chain fatty acid concentrations 
in humans. Metabolism. 1997;46(7):805–811.
  7.  Schwiertz A, Taras D, Schafer K, et al. Microbiota and SCFA 
in lean and overweight healthy subjects. Obesity (Silver Spring). 
2010;18(1)190–195.
  8.  Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G.   
Insulin  resistance  and  hypersecretion  in  obesity.  European 
Group for the Study of Insulin Resistance (EGIR). J Clin Invest. 
1997;100(5):1166–1173.
  9.  Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by 
nutrients and inflammation. J Clin Invest. 2008;118(9):2992–3002.
  10.  Sivan E, Boden G. Free fatty acids, insulin resistance, and pregnancy. 
Curr Diab Rep. 2003;3(4):319–322.
  11.  Nolan CJ, Madiraju MS, Delghingaro-Augusto V , Peyot ML, Prentki M. 
Fatty acid signaling in the beta-cell and insulin secretion. Diabetes. 
2006;55 Suppl 2:S16–S23.
  12.  Ximenes HM, Hirata AE, Rocha MS, Curi R, Carpinelli AR. Propionate 
inhibits glucose-induced insulin secretion in isolated rat pancreatic 
islets. Cell Biochem Func. 2007;25(2):173–178.
  13.  American Diabetes Association. Standards of medical care in   
diabetes – 2010. Diabetes Care. 2010;33 Suppl 1:S11–S61.
  14.  Legro RS, Driscoll D, Strauss JF 3rd, Fox J, Dunaif A. Evidence for 
a genetic basis for hyperandrogenemia in polycystic ovary syndrome. 
Proc Nat Acad Sci U S A. 1998;95(25):14956–14960.
  15.  Dunaif A, Wu X, Lee A, Diamanti-Kandarakis E. Defects in insulin 
receptor signaling in vivo in the polycystic ovary syndrome (PCOS). 
Am J Physiol. 2001;281(2):E392–E399.
  16.  Vogt JA, Pencharz PB, Wolever TM. L-Rhamnose increases serum 
propionate in humans. Am J Clin Nutr. 2004;80(1):89–94.
  17.  Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T.   
Evidence for distinctive and intrinsic defects in insulin action in poly-
cystic ovary syndrome. Diabetes. 1992;41(10):1257–1266.
  18.  Jensen MD, Kanaley JA, Reed JE, Sheedy PF. Measurement of abdomi-
nal and visceral fat with computed tomography and dual-energy x-ray 
absorptiometry. Am J Clin Nutr. 1995;61(2):274–278.
  19.  Lopez S, Bermudez B, Abia R, Muriana FJ. The influence of major 
dietary fatty acids on insulin secretion and action. Curr Opin Lipidol. 
2010;21(1):15–20.
  20.  Despres JP, Lemieux I, Prud’homme D. Treatment of obesity: 
need to focus on high risk abdominally obese patients. BMJ. 
2001;322(7288):716–720.
  21.  Demerath EW, Reed D, Rogers N, et al. Visceral adiposity and its 
anatomical distribution as predictors of the metabolic syndrome 
and cardiometabolic risk factor levels. Am J Clin Nutr. 2008;88(5): 
1263–1271.
  22.  Rytka JM, Wueest S, Schoenle EJ, Konrad D. The portal theory sup-
ported by venous drainage-selective fat transplantation. Diabetes. 
2011;60(1):56–63.
  23.  Skutches CL, Holroyde CP, Myers RN, Paul P, Reichard GA. Plasma 
acetate turnover and oxidation. J Clin Invest. 1979;64(3):708–713.
  24.  Manzo-Avalos S, Saavedra-Molina A. Cellular and mitochondrial 
effects of alcohol consumption. Int J Environ Res Public Health. 
2010;7(12):4281–4304.
  25.  Pouteau E, Piloquet H, Maugeais P, et al. Kinetic aspects of acetate 
metabolism in healthy humans using [1-13C] acetate. Am J Physiol. 
1996;271(1 Pt 1):E58–E64.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
53
Association of adiposity with acetateDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5
  26.  Tollinger CD, Vreman HJ, Weiner MW. Measurement of acetate in 
human blood by gas chromatography: effects of sample preparation, 
feeding, and various diseases. Clin Chem. 1979;25(10):1787–1790.
  27.  Zaibi MS, Stocker CJ, O’Dowd J, et al. Roles of GPR41 and GPR43 in 
leptin secretory responses of murine adipocytes to short chain fatty 
acids. FEBS Lett. 2010;584(11):2381–2386.
  28.  Tolhurst G, Heffron H, Lam YS, et al. Short-chain fatty acids stimulate 
glucagon-like peptide-1 secretion via the G-protein-coupled receptor 
FFAR2. Diabetes. 2012;61(2):364–371.
  29.  Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G protein-
coupled receptors GPR41 and GPR43 are activated by propionate 
and other short chain carboxylic acids. J Biol Chem. 2003;278(13): 
11312–11319.
  30.  Hong YH, Nishimura Y, Hishikawa D, et al. Acetate and propi-
onate short chain fatty acids stimulate adipogenesis via GPCR43. 
  Endocrinology. 2005;146(12):5092–5099.
  31.  Karaki S, Mitsui R, Hayashi H, et al. Short-chain fatty acid receptor, 
GPR43, is expressed by enteroendocrine cells and mucosal mast cells 
in rat intestine. Cell Tissue Res. 2006;324(3):353–360.
  32.  Karaki S, Tazoe H, Hayashi H, et al. Expression of the short-chain 
fatty acid receptor, GPR43, in the human colon. J Mol Histol. 
2008;39(2):135–142.
  33.  Nilsson NE, Kotarsky K, Owman C, Olde B. Identification of a 
free fatty acid receptor, FFA2R, expressed on leukocytes and acti-
vated by short-chain fatty acids. Biochem Biophys Res Commun. 
2003;303(4):1047–1052.
  34.  Regard JB, Kataoka H, Cano DA, et al. Probing cell type-specific func-
tions of G(i) in vivo identifies GPCR regulators of insulin secretion.   
J Clin Invest. 2007;117(12):4034–4043.
  35.  Gutin B, Johnson MH, Humphries MC, et al. Relationship of visceral 
adiposity to cardiovascular disease risk factors in black and white teens. 
Obesity (Silver Spring). 2007;15(4):1029–1035.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
54
Layden et alDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-targets-and-therapy-journal
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy is 
an international, peer-reviewed open-access journal committed to 
the rapid publication of the latest laboratory and clinical findings 
in the fields of diabetes, metabolic syndrome and obesity research.   
Original research, review, case reports, hypothesis formation, expert 
opinion and commentaries are all considered for publication. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5
Table S1 Obesity, oral glucose tolerance test and hyperinsulinemic euglycemic clamp data in a cohort of 18 obese womena
Measures Total (n = 18) PCOS (n = 7) Non-PCOS (n = 11) Pb
Obesity
VAT 83 (10) 75 (16) 87 (13) 0.54
FAT (kg) 39 (3) 38 (6) 40 (3) 0.69
OGTT
Fasting glucose (mg/dL) 93.6 (1.4) 92.4 (2.5) 94.3 (2.5) 0.83
2 hour glucose (mg/dL) 117.9 (5.8) 132.7 (9.2) 108.6 (6.2) 0.048
Fasting insulin (µU/mL) 16.9 (2.3) 15.9 (3.5) 17.5 (3.1) 0.54
2 hour insulin (µU/mL) 83.8 (12.4) 114.0 (21.2) 64.5 (12.6) 0.038
Clampc
EgP (mg/m2/min) 78.9 (4.5) 78.3 (6.1) 79.3 (6.5) 0.92
DI (IS × ∆I30) 21.9 (2.8) 21.2 (3.6) 22.6 (3.5) 0.81
MCr (mL/min) 320.3 (21.8) 295.8 (28.6) 338.6 (31.4) 0.35
IMgD (mg/m2/min) 510.6 (26.0) 477.2 (39.2) 535.6 (34.1) 0.28
Notes: aValues are the mean and standard error of mean (in parentheses); bP-values are shown in this column comparing parameters between PCOS versus non-PCOS 
subjects; VAT was determined by computerized tomography scan, and FAT was determined by dual photon X-ray absorptiometry scan; cfor the hyperinsulinemic euglycemic 
clamp studies, the basal and steady state glucose (mg/dL) levels (mean ± SD) were 84.4 ± 4.1, n = 18 and 84.1 ± 3.9, n = 15 and the basal and steady state insulin (µU/mL) 
levels (mean ± SD, n = 18) were 16.1 ± 7.1, n = 18, and 1853 ± 258, n = 15; there were no statistical differences in these values between non-PCOS and PCOS subjects.
Abbreviations:  PCOS,  polycystic  ovary  syndrome;  VAT,  visceral  adipose  tissue;  FAT,  percentage  fat  mass  ×  body  weight;  OgTT,  oral  glucose  tolerance  test;   
EgP, endogenous glucose production; DI, disposition index; MCr, metabolic clearance rate of insulin; IMgD, insulin mediated glucose disposal.
Table S2 Associations between short chain fatty acids and measures of obesity and insulin action/secretion based on PCOS statusa
Measures Acetate (μM) Propionate (μM) Butyrate (μM)
Obesity
BMI (kg/m2) -0.04, -0.43 -0.02, 0.46 -0.10, 0.25
VAT -0.60, -0.58 0.11, 0.21 -0.04, 0.52
FAT (kg) -0.22, -0.52 0.04, 0.66 0.16, 0.08
OGTT
Fasting glucose (mg/dL) -0.29, -0.25 0.10, -0.16 0.02, 0.54
2 hour glucose (mg/dL) -0.51, -0.24 0.10, -0.21 -0.30, 0.33
Fasting insulin (µU/mL) -0.62 (0.04),b -0.66 0.22, 0.32 -0.07, 0.81 (0.03)b
2 hour insulin (µU/mL) -0.54, -0.66 0.26, 0.56 0.01, 0.74
Clamp
EgP (mg/m2/min) 0.31, -0.71 0.54, 0.08 0.60, -0.21
DI (IS × ∆I30) -0.72,c 0.44 0.50, -0.65 -0.27, 0.22
MCr (mL/min) -0.46, 0.18 0.30, -0.26 -0.38, 0.05
IMgD (mg/m2/min) 0.34, -0.21 -0.09, 0.51 0.35, 0.32
Notes: aCorrelation coefficients (Pearson) between short chain fatty acids and measures of obesity and values derived from the OGTT and hyperinsulinemic euglycemic 
clamp are shown. In each column, the first value is the correlation in non-PCOS subjects and the second in PCOS subjects; bP-values reaching statistical significance are 
indicated in the parentheses; cof note, a significant association between acetate and DI was not found despite high correlation value because only seven non-PCOS subjects 
had DI values calculated.
Abbreviations: PCOS, polycystic ovary syndrome; BMI, body mass index; VAT, visceral adipose tissue; FAT, percentage fat mass × body weight; OgTT, oral glucose 
tolerance test; EgP, endogenous glucose production; DI, disposition index; MCr, metabolic clearance rate of insulin; IMgD, insulin mediated glucose disposal.
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Association of adiposity with acetate